Four years af­ter near-death ex­pe­ri­ence, PhI­II da­ta bring good news for No­vavax

No­vavax is cel­e­brat­ing tri­al re­sults again four years af­ter a Phase III fail­ure in RSV sent their stock price off a cliff.

The com­pa­ny an­nounced that their re­com­bi­nant flu vac­cine NanoFlu met all pri­ma­ry and sec­ondary end­points in a Phase III study of 2,652 adults old­er than 65. The num­bers, No­vavax sug­gest­ed, should al­low them to clear reg­u­la­to­ry hur­dles and snag the biotech’s first ap­proval since its found­ing in 1987.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER